Scrotal testosterone patches: A good supplement to treatment possibilities of hypogonadal men;Scrotale testosteronpleisters: Een goede aanvulling op de behandelingsmogelijkheden voor hypogonadisme bij de man

Nederlands Tijdschrift voor Geneeskunde

Volumn 144, Issue 18, 2000, Pages 847-850

  Asscheman, H ^a   Gooren, L J G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; ANDROGEN THERAPY; ARTICLE; CLINICAL ARTICLE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; PROSPECTIVE STUDY; SKIN TOXICITY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; DIHYDROTESTOSTERONE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; LIBIDO; MALE; MIDDLE AGED; PATIENT DROPOUTS; SCROTUM; SEX; TESTOSTERONE; TREATMENT OUTCOME;

EID: 0034728869     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Nieschlag E. Behre HM. Pharmacology and clinical uses of testosterone. In: Nieschlag E, Behre HM, editors. Testosterone: action, deficiency, substitution. Berlijn: Springer; 1998. p. 293-348.
2. Gooren LJG. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994;15:212-5.
3. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 1981;14: 49-61.
4. Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986;ii:943-6.
5. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989;68:369-73.
6. Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1989; 261:2525-30.
7. Atkinson LE, Chang Y, Snyder PJ. Long-term experience with testosterone replacement through scrotal skin. In: Nieschlag E, Behre HM, editors. Testosterone: action, deficiency, substitution. Berlijn: Springer: 1998. p. 365-88.
8. Schaison G, Couzinet B. Percutaneous dihydrotestosterone treatment. In: Nieschlag E, Behre HM, editors. Testosterone: action, deficiency, substitution. Berlijn: Springer: 1998. p. 423-36.
9. Gooren LJG. Androgen levels and sex functions in testosterone treated hypogonadal men. Arch Sex Behav 1987;16:463-73.
10. Finkelstein JS. Androgens and bone metabolism. In: Nieschlag E, Behre HM, editors. Testosterone: action, deficiency, substitution. Berlijn: Springer; 1998. p. 187-207.
11. Behre HM. Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-90.
12. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L. Sanders SW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endoerinol (Oxf) 1997;47:727-37.
13. Jordan jr WP. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermal 1997;8:108-13.